Tonix Pharmaceuticals Holding Corp. (TNXP) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 13.22 |
| Open | 12.8 |
| Day High | 13.3 |
| Day Low | 12.7 |
| 52-Week High | 69.97 |
| 52-Week Low | 10.03 |
| Volume | 520,255 |
| Average Volume | 494,945 |
| Market Cap | 203.25M |
| PE | -0.89 |
| EPS | -14.36 |
| Moving Average 50 Days | 12.82 |
| Moving Average 200 Days | 16.46 |
| Change | -0.47 |
Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia
GlobeNewswire Inc.
Mar 10, 2026 12:00 PM GMT
Company launched TONMYA, approved by the FDA as a treatment for fibromyalgia, in November 2025 In post hoc analysis of the pivotal RESILIENT study, TONMYA produced rapid pain relief as early as Day 2 of treatment, with durable pain reduction and sign
Tonix Pharmaceuticals Presented Data on TONMYA™ in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting
GlobeNewswire Inc.
Mar 09, 2026 8:30 PM GMT
TONMYA (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, was commercially launched in November 2025Treatment with TONMYA provided statistically significant pain reduction in two Phase 3 trials and was generally wel
Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting
GlobeNewswire Inc.
Mar 09, 2026 8:30 PM GMT
TONMYA (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, was commercially launched in November 2025 Treatment with TONMYA provided statistically significant pain reduction in two Phase 3 trials and was generally we